The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Inotuzumab ozogamicin (InO) treatment in patients with relapsed/refractory acute lymphoblastic leukemia (R/R ALL): Outcomes of patients treated in salvage one with a long duration of first remission.
 
Hagop M. Kantarjian
Honoraria - Abbvie; Amgen; ARIAD; Bristol-Myers Squibb; Immunogen; Orsenix; Pfizer
Research Funding - Amgen (Inst); ARIAD (Inst); Astex Pharmaceuticals (Inst); Bristol-Myers Squibb (Inst); Novartis (Inst); Pfizer (Inst)
 
Matthias Stelljes
Honoraria - Pfizer
Consulting or Advisory Role - Amgen; Pfizer
Speakers' Bureau - Pfizer
Research Funding - Pfizer
Travel, Accommodations, Expenses - Meda; Neovii; Pfizer
 
Anjali S. Advani
Honoraria - EUSA Pharma; Pfizer; Sigma-Tau
Consulting or Advisory Role - Glycomimetics; Novartis; Pfizer; Seagen
Research Funding - KaloBios (Inst); Millennium (Inst); Pfizer (Inst); Seagen (Inst)
 
Daniel J. DeAngelo
Consulting or Advisory Role - Amgen; ARIAD; Bristol-Myers Squibb; Celgene; Immunogen; Incyte; Novartis; Pfizer; Shire
 
David I. Marks
No Relationships to Disclose
 
Wendy Stock
Consulting or Advisory Role - Adaptive Biotechnologies; Jazz Pharmaceuticals
Research Funding - Sigma-Tau (Inst)
Patents, Royalties, Other Intellectual Property - Royalties for a chapter in Up to Date
 
Susan Mary O'Brien
Employment - University of California, Irvine
Honoraria - Abbvie; Alexion Pharmaceuticals; Amgen; Aptose Biosciences; Astellas Pharma; Celgene; Eisai; Gilead Sciences; GlaxoSmithKline; Janssen; Loxo; Pfizer; Pharmacyclics; Sunesis Pharmaceuticals; TG Therapeutics; Vaniam Group
Consulting or Advisory Role - Abbvie/Genentech; Alexion Pharmaceuticals; Amgen; Aptose Biosciences; Astellas Pharma; Celgene; Gilead Sciences; GlaxoSmithKline; Janssen Oncology; Pfizer; Pharmacyclics; Sunesis Pharmaceuticals; Sunesis Pharmaceuticals; TG Therapeutics; Vaniam Group
Research Funding - Acerta Pharma (Inst); Gilead Sciences (Inst); Kite, a Gilead company (Inst); Pfizer (Inst); Pharmacyclics (Inst); Regeneron (Inst); Sunesis Pharmaceuticals (Inst); TG Therapeutics (Inst)
Travel, Accommodations, Expenses - Celgene; Gilead Sciences; Janssen; Janssen Oncology; Regeneron
 
Ryan Daniel Cassaday
Employment - Seagen (I)
Stock and Other Ownership Interests - Seagen (I)
Honoraria - Pfizer
Consulting or Advisory Role - Adaptive Biotechnologies; Amgen; Jazz Pharmaceuticals
Research Funding - Amgen (Inst); Gilead Sciences (Inst); Incyte (Inst); Kite, a Gilead company (Inst); Merck (Inst); Pfizer (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Amgen
 
Tao Wang
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Alexander Neuhof
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Erik Vandendries
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Elias Jabbour
Consulting or Advisory Role - Abbvie; Adaptive Biotechnologies; Amgen; Astellas Pharma; Bristol-Myers Squibb; Incyte; Pfizer; Takeda
Research Funding - Abbvie; Adaptive Biotechnologies; Amgen; Pfizer; Takeda